Effects of different doses of sufentanil on the median effective concentration of remazolam during gastroenteroscopy in patients with cirrhosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050674

Enrollment

Unknown

Registered

2021-09-01

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscope and Painless colonoscopy

Interventions

Control group:saline

Experimental group1:The dose of Sufentanil

Experimental group2:The dose of Sufentanil

Experimental group3:The dose of Sufentanil

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Informed consent for surgery and anesthesia has been obtained from patients and their families; 2. Aged 18 to 65 years; 3. ASA classification II-III; 4. Child-Pugh classification of liver function is A; 5. In line with the indications for painless gastroscopy.

Exclusion criteria

Exclusion criteria: 1. Allergic to the test drug; 2. Long-term use of sedative and analgesic drugs, alcohol dependence, drug addiction; 3. Patients who cannot complete follow-up.

Design outcomes

Primary

Measure	Time frame
body response;	—

Secondary

Measure	Time frame
hemodynamics;Respiratory depression;Pain assessment;Calm assessment;	—

Countries

China

Contacts

Public ContactLiu Peng

The Third Hospital of Hebei Medical University

liupeng2010aa@126.com+86 13284473704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026